Dr. Edwards joined Acer as Vice President of Clinical Sciences in August 2021. He brings to Acer 16 years of experience in various aspects of drug development including DMPK, Clinical Pharmacology and Clinical Science. Dr. Edwards has been involved in the discovery and development of multiple new chemical entities for the treatment of obesity, diabetes, inflammation, autoimmune, primary biliary cholangitis (PBC), and non-alcoholic steatohepatitis (NASH). Previously, he served as Vice President of Clinical Science at Madrigal Pharmaceuticals, and positions of increasing responsibility at Intercept Pharmaceuticals, Amylin Pharmaceuticals, and Arena Pharmaceuticals. Dr. Edwards received his B.S degree in Chemistry from James Madison University and a Ph.D. in Toxicology from the University of Kentucky.
